Medical researchers in Japan have discovered a way to predict a potentially life-threatening side effect of cancer immunotherapy before it occurs. By analyzing cerebrospinal fluid collected ...
In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback